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Abstract
Background: Prescription practices have been shown to influence the emergence of anti-malarial drug resistance. Thus efforts
in this study were devoted to evaluating the prescribing practices prior to introduction of the artemisinin based combination
therapy (ACT) in Nigeria and its potential contribution to emergence of chloroquine resistant malaria in south-west Nigeria, in
order to forestall a similar situation with the ACT.
Methods: A retrospective quantitative study was designed to examine case records of patients treated for malaria in either a
government or a private hospital in Ibadan, south-west Nigeria, over a 20-year period, cutting across three phases of resistance
to chloroquine in Nigeria: pre-resistance, emerging resistance and dissemination of resistance. Patient prescriptions were
examined for use of anti-malarial drugs, sub-therapeutic doses of chloroquine, co-administration of anti-histamines with
chloroquine. Descriptive statistics of frequency and percentage were used to describe trends in the parameters assessed using
EPI-info.
Results: Case record files of 2,529 patients were examined. Chloroquine was the main drug used in treatment of malaria
throughout the periods studied, with frequency of prescription at both sites ranging from 91.4% to 98.3% during the pre-
resistance years. It was administered as standard doses during the pre resistance years. Anti-histamines, especially promethazine,
were routinely co-administered with chloroquine at this period too. However, the practice of prescribing sub-therapeutic doses
of chloroquine at the private health care facility coincided with the latter phase of emerging resistance and phase of dissemination
of resistance. Frequency of prescription of sub-therapeutic doses increased from 6.7% in 1983 (pre-resistance years) to 43.6%
in 1997 (dissemination of resistance phase) at the private health care facility. Frequency of co-administration of anti-histamines
with chloroquine also reduced during the period of dissemination of resistance.
Conclusion: The results from this study describe a lack of adherence to national treatment guidelines, especially in the private
sector, and a relationship between prescription practices and dissemination of drug resistant falciparum malaria. As Nigeria
adopts the use of ACT, there is an urgent need to improve malaria treatment practices in Nigeria in order to prolong the clinical
shelf-life of the combination.
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Background
The change in malaria control policy in Nigeria in 2005 in
favour of artemisinin-based combination therapy (ACT)
became necessary with the prevalence of Plasmodium falci-
parum  resistance to chloroquine and sulphadoxine-
pyrimethamine [1-6]. Prescription practices have been
shown to influence the emergence of resistance to anti-
malarial drugs [7,8], thus the success of a new treatment
policy would depend on the adherence of health provid-
ers and patients to treatment recommendations [9]. This
becomes important in order to protect the clinical shelf-
life of the artemisinin-based combinations since they
remain the most valuable drugs currently available for the
management of malaria. Irrational use of ACT could
undermine one of the goals of combination therapy,
which is to prevent the emergence of resistant malaria par-
asites. Drug use patterns can be evaluated in terms of pre-
scribing and dispensing practices as well as patients' use of
the drug. The private sector has been shown to be respon-
sible for treating half of the malaria cases in Nigeria [10]
and the role of prescription practices in the emergence of
anti-malarial drug resistance in Nigeria has not been fully
elucidated.
This study focused on evaluating the prescribing practices
of medical practitioners in public and private hospitals
prior to introduction of ACT in Nigeria and the potential
contribution of the prescribing practices to the emergence
of chloroquine resistant malaria in south-west Nigeria, in
order to forestall a repeat of this with ACT. It is hoped that
the study would provide valuable guidelines on the use of
ACT in Nigeria in order to prolong the clinical utility of
the drug. A retrospective study was designed to examine
case records of patients treated for malaria in two major
government-owned and private hospitals in Ibadan over a
20-year period.
Methods
Ethical clearance was obtained from the joint University
of Ibadan/University College Hospital Ethical Commit-
tee.
Study site
The retrospective study was conducted in Ibadan, south-
west Nigeria. Malaria is hyper-endemic in the area with
perennial transmission. The climate is that of tropical
rainforest zone, with a warm dry-season from November
to April and a rainy season from May to October. The
study was originally designed to evaluate patient case
records at three government-owned hospitals and private
clinics in Ibadan, but most of the hospitals lacked the
records required for the study or prevented access to the
records. The study was thus conducted at only two sites, a
government-owned hospital and a major private hospital
in Ibadan, with an evaluation of case records files from the
male, female and children's wards.
Data collection
The data were collected in 2001. The retrospective study
on prescription pattern was conducted across three phases
of resistance to chloroquine in Nigeria; pre-resistance
phase (1980-1986), phase of emerging resistance (1987-
1993) and phase of dissemination of resistance (1994-
2000). The data from case record files were evaluated if
the following information were available: diagnosis for
malaria, prescription of anti-malarial drugs, indication of
dose administered and duration of therapy, patient medi-
cal history, especially previous use of anti-malarial drugs
prior to hospital visit. The following information were
obtained from the case record files: the number of times
of prescription of each anti-malarial drug (chloroquine,
sulphadoxine-pyrimethamine, quinine, amodiaquine,
mefloquine or halofanthrine) per annum, the number of
times of prescription of sub-therapeutic doses of chloro-
quine (< 25 mg/kg body weight) across the selected
period, rate of co-administration of resistance modulating
agents such as antihistamines or calcium channel antago-
nists with chloroquine, relative use of various types of
resistance modulators co-administered with chloroquine
and the number of times of co-administration of other
drugs with anti-malarial properties (co-trimoxazole, anti-
biotics). Descriptive statistics of frequency and percentage
were used to describe trends in the parameters assessed
using EPI-info. Chi-square tests were used to compare
proportions of appropriate prescriptions over the years.
Trend of development of resistance to chloroquine in
Nigeria during the period studied was obtained from pub-
lished studies.
Results
A total of 2,190 patient case notes were evaluated at the
private hospital during the study of prescription pattern
and at least 300 case notes were evaluated for each of the
selected years. A total of 339 case notes were evaluated at
the Government owned hospital (being a referral centre
for complicated cases). Malaria was diagnosed in all the
patients by microscopic examination of blood films in
addition to clinical signs and symptoms of malaria.
Prescription of anti-malarial drugs
In the pre-resistance years (1980-1986) chloroquine (CQ)
was the most commonly prescribed anti-malarial drug
accounting for 94.8% to 97.4% of anti-malarial drug pre-
scription at the private hospital between 1983 and 1985
(Table 1). Other anti-malarial drugs prescribed during this
period included sulphadoxine-pyrimethamine (SP) and
amodiaquine (AQ) (frequency of prescription was 2.4%
and 2.8% respectively). A progressive reduction in pre-
scription of CQ through the phases of emerging resistanceMalaria Journal 2009, 8:313 http://www.malariajournal.com/content/8/1/313
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(1987-1989) and the resistance dissemination phase
(1990-1997) was observed. The frequency of prescription
of SP and AQ increased to 4.1% and 24.7% respectively in
1989. Quinine (QN) was also used during this period, but
frequency of prescription was very low (0.3%). By 1997,
frequency of prescription of SP had increased to 13.4%.
Other anti-malarial drugs prescribed during this period
included halofanthrine and artemether as monotherapy
(frequency of prescription was 3.1% and 1.6% respec-
tively) (Table 1).
Similarly, in the government-owned hospital, CQ was the
most commonly prescribed anti-malarial drug during the
pre-resistance years. Amodiaquine was the only other
anti-malarial drug prescribed during the pre-resistance
years. However, frequency of prescription of CQ at the
Table 1: Frequency of prescription of anti-malarial drugs at a private hospital in Ibadan, south-west Nigeria, over a twenty-year 
period.
YEAR CQ SP AQ QN PY PG HAL ART
1983
N = 303
94.8% 2.3% 2.8% 0 0.3% 0 0 0
1985
N = 306
97.4% 0.7% 1.0% 0 0.3% 0 0 0
1987
N = 304
95.5% 1.9% 0.6% 0 1.0% 1.0% 0 0
1989
N = 320
67.1% 4.1% 24.7% 0.3% 0.9% 1.3% 0 0
1992
N = 322
80.1% 10.2% 0.6% 0.9% 0.3% 1.2% 5.9% 0
1995
N = 314
77.4% 10.2% 4.1% 1.9% 0.6% 1.9% 3.8% 0
1997
N = 321
73.7% 13.4% 2.8% 2.2% 0 1.9% 3.1% 1.6%
CQ = Chloroquine; SP = Sulphadoxine/Pyrimethamine; AQ = Amodiaquine; QN = Quinine; PY = Pyrimethamine; PG = Proguanil; HAL = 
Halofantrine; ART = Artemether
Table 2: Variation in prescription of anti-malarial drugs at a government-owned hospital in Ibadan, southwest Nigeria over a twenty-
year period.
Year CQ SP AQ QN PY PG HAL ART
1983
N = 57
9 8 . 3 % 0000 1 . 7 % 0 0
1985
N = 58
91.4% 0 1.7% 0 6.9% 0 0 0
1987
N = 58
89.7% 0 0 0 10.3% 0 0 0
1989
N = 57
80.7% 0 10.5% 3.5% 3.5% 1.8% 0 0
1992
N = 57
86% 12.3% 0 0 0 0 1.7% 0
1995
N = 57
68.4% 15.8% 0 10.5% 1.8% 0 1.8% 1.8%
1997
N = 57
82.5% 8.8% 0 7.0% 0 0 0 1.7%
CQ = Chloroquine; SP = Sulphadoxine/Pyrimethamine; AQ = Amodiaquine; QN = Quinine; PY = Pyrimethamine; PG = Proguanil; HAL = 
Halofantrine; ART = ArtemetherMalaria Journal 2009, 8:313 http://www.malariajournal.com/content/8/1/313
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hospital reduced from 98.3% in 1983 to 80.7% in 1989
and 68.4% in 1995 during the phases of emerging resist-
ance and resistance dissemination respectively (Table 2).
In 1989 the frequency of use of AQ and QN were 10.5%
and 3.5% respectively. Between 1992 and 1997 the fre-
quency of use of sulphadoxine-pyrimethamine varied
between 8.8% and 15.8% while use of quinine increased
to 10.5% in 1995. Halofanthrine and artemether were
also prescribed between 1992 and 1997 though the fre-
quency of prescription was low (1.7% to 1.8%) (Table 2).
Usage of sub-therapeutic doses of chloroquine
In the private hospital, frequency of prescription of sub-
therapeutic dose regimen of chloroquine was low during
the pre-resistance phase and varied between 1.7% and
6.9% (Table 3). However during the resistance dissemina-
tion phase (1994-2000) an increase in frequency of pre-
scription of sub-therapeutic doses of CQ varying between
27.2% and 43.6% was observed (Table 3). Of the 587
patient records observed in the pre-resistance years 562
(95.7%) patients received full regimen of chloroquine
compared with 25 (4.3%) that received sub-therapeutic
doses of CQ. However, in the dissemination of resistance
phase, 313/484 patients (64.6%) received standard doses
of CQ while 171/484 (35.3%) patients received sub-ther-
apeutic doses of CQ. These proportions were significantly
different X2 = 233.03, P < 0.0001. At the Government
owned hospital, frequency of prescription of sub-thera-
peutic doses of chloroquine varied between 5.4% and
5.7% during the pre-resistance phase (Table 4) and
remained low (0-7.7%) throughout the periods of emerg-
ing or dissemination of resistance (X2 = 1.72, P = 0.189).
Co-administration of chloroquine with adjunct drugs
Chloroquine was routinely co-administered with various
antihistamines or antiemetic including promethazine,
chlorpheniramine, cyproheptadine, diphenhydramine or
chlorpromazine during the period studied at the private
hospital (Table 5). Frequency of prescription of prometh-
azine was highest throughout the phases studied. During
the pre-resistance phase, frequency of prescription of pro-
methazine ranged from 74% to 76% while that of chlo-
rpheniramine ranged between 5% to 6.5%. A significant
decline in frequency of prescription of promethazine was
observed during the phases of emerging resistance and
dissemination of resistance (X2 = 83.04, P < 0.0001),
while frequency of prescription of chlorpheniramine sig-
nificantly increased during these periods to 34% to 47%
(P < 0.0001).
At the government-owned hospital, anti-histamines or
anti-emetics, including promethazine, chlorpheniramine,
diphenhydramine, chlorpromazine, cyproheptadine and
pizotifen, were also routinely prescribed with chloroquine
(Table 6). Promethazine was most frequently co-adminis-
tered with chloroquine until 1997 when chlorphe-
niramine became the most frequently co-administered
anti-histamine. Anti-histamines were routinely prescribed
with chloroquine throughout the period studied at the
government-owned hospital to reduce vomiting and/or
chloroquine-induced itching. Frequency of co-adminis-
tration of chlorpheniramine with chloroquine was 75%
in 1997, when the frequency of use of promethazine
decreased to 25%.
Table 3: Frequency of prescription of complete therapeutic regimen or sub-therapeutic regimen of chloroquine over a twenty-year 
period at a private hospital in Ibadan, south-west Nigeria
Full course regimen Sub-therapeutic regimen
YEAR N F N F
1983 (N = 289) 269 93.1% 20 6.9% Pre-resistance phase
1985 (N = 298) 293 98.3% 5 1.7%
1987 (N = 295) 284 96.3% 11 3.7% Phase of emerging resistance
1989 (N = 220) 214 97.3% 6 2.7%
1992 (N = 258) 202 78.3% 56 21.7%
1995 (N = 243) 177 72.8% 66 27.2% Phase of resistance dissemination
1997 (N = 241) 136 56.4% 105 43.6%
N = No. of prescriptions evaluated
F = Frequency of prescriptionMalaria Journal 2009, 8:313 http://www.malariajournal.com/content/8/1/313
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Trends of chloroquine sensitivity in south-west Nigeria
The prescription practices at the private hospital based on
use of therapeutic or sub-therapeutic dosages as well as co-
administration of anti-histamines with chloroquine were
collated with the reported trends of chloroquine sensitiv-
ity in south-west Nigeria (Table 7). The reported clinical
sensitivity of Plasmodium falciparum to chloroquine
decreased from 100% in the pre-resistance years to 40% in
the resistance dissemination years. During the period of
dissemination of resistance there were corresponding
decreases in the frequency of prescription of full course
treatment regimen of chloroquine and co-administration
of antihistamines from 93% to 56% and 74% to 51%
respectively.
Discussion
The study was conducted in two hospitals, a government
health care facility and a private health care facility. The
record keeping at the private health care facility was excel-
lent and permitted a retrospective study over the period
Table 4: Frequency of prescription of complete therapeutic regimen or sub-therapeutic regimen of chloroquine at a government-
owned hospital in Ibadan, southwest Nigeria over a twenty-year period.
Full course regimen Sub-therapeutic regimen
Year N F N F
1983
(n = 56)
53 95% 3 5.4% Pre-resistance phase
1985
(n53)
50 94.3% 3 5.7%
1987
(n = 52)
52 100% 0 0 Phase of emerging resistance
1989
(n = 46)
46 100% 0 0
1992
(n = 49)
47 95.9% 2 4.1%
1995
(n = 39)
36 92.3% 3 7.7% Phase of resistance dissemination
1997
(n = 47)
47 100% 0 0
N = No. of prescriptions evaluated
F = Frequency of prescription
Table 5: Antihistamines co-administered with chloroquine over a twenty-year period at a private hospital in Ibadan, south-west 
Nigeria
Promethazine Chlorpheniramine Cyproheptadine Others
YEAR N F N F N F N F
1983 170 74% 11 5% 3 3% 45 20%
1985 209 75.7% 18 6.5% 1 0.4% 48 17.4%
1987 181 63.7% 39 13.7% 4 1.4% 60 21.1%
1989 86 49.1% 70 40% 0 0 19 10.9%
1992 103 52.0% 75 37.8% 0 0 20 10.1%
1995 51 43.2% 55 46.6 3 2.5% 15 12.7%
1997 62 44.3% 48 34.3% 8 5.7% 22 15.7%
N = No. of prescriptions evaluated
F = Frequency of prescriptionMalaria Journal 2009, 8:313 http://www.malariajournal.com/content/8/1/313
Page 6 of 8
(page number not for citation purposes)
chosen. Record-keeping at the government health care
facility was quite different with categorization of certain
records as secondary records and thus stored away with
limited access. This practice did not permit full access to
the records required for the retrospective study. Availabil-
ity of modern medical record system has been identified
as a key factor facilitating clinical audit [11], thus modern-
izing medical record systems in Nigeria will be valuable in
development of clinical auditing. The private sector is a
leading provider of malaria case management in many
endemic countries [12], which was also evidenced in this
study. The results from the study show that during the pre-
resistance years chloroquine was the main drug used in
the chemotherapy of malaria in both sectors of health care
provision. It was administered as standard doses during
this period and anti-histamines, especially promethazine,
Table 6: Relative frequency of antihistamines co-administered with chloroquine at government owned hospital.
Promethazine Chlorpheniramine Cyproheptadine Others
NF N F N F N F
1983
N = 25
16 64% 4 16% 0 0 5 20%
1985
N = 25
14 56% 1 4% 0 0 10 40%
1987
N = 30
21 70% 1 3.3% 0 0 8 26.7%
1989
N = 23
15 65.2% 1 4.3% 0 0 7 30.4%
1992
N = 9
88 8 . 9 % 1 1 1 . 1 % 0 0 0 0
1995
N = 9
6 66.7% 2 22.2% 0 0 1 1.1%
1997
N = 4
12 5 % 3 7 5 % 0 0 0 0
N = No. of prescriptions evaluated
F = Frequency of prescription
Table 7: Trends in chloroquine sensitivity profiles during periods of co-administration of antihistamines with chloroquine or use of sub-
therapeutic dosage regimen in patients from a private hospital in Ibadan, south-west Nigeria
Year Frequency of co-
administration of 
antihistamine
Frequency of prescription of 
Full course regimen
Frequency of sub-
therapeutic regimen
Reported chloroquine 
sensitivity
1983 (N = 289) 74.7% 93.1% 6.9% 100% [19,20]
1985 (N = 298) 80.0% 98.3% 1.7%
1987 (N = 295) 84.4% 96.3% 3.7% 100% [21]
1989 (N = 220) 72.3% 97.3% 2.7%
1992 (N = 258) 67.4% 78.3% 21.7% 85% [22]
1995 (N = 243) 48.6% 72.8% 27.2%
1997 (N = 241) 51.9% 56.4% 43.6% <40%([3]Malaria Journal 2009, 8:313 http://www.malariajournal.com/content/8/1/313
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were routinely co-administered with chloroquine. The
practice of prescribing sub-therapeutic doses of chloro-
quine became prominent between 1992 and 1997 which
coincided with the emerging resistance and resistance dis-
semination phases and revealed deficiencies in the private
sector in relation to poor adherence to National and
WHO guidelines for malaria. Poor drug use practices such
as the use of sub-therapeutic doses, are among factors that
can lead to the emergence and spread of drug resistant
strains of Plasmodium falciparum ([7] and this was evident
in this study. The government-owned hospital, which is
also a tertiary institution, adhered to National and WHO
guidelines for malaria treatment. The findings from this
study are consistent with previous reports [13] that pre-
scribers in government health facilities tend to adhere
more to national treatment guidelines than private practi-
tioners. These findings pose a huge challenge to national
treatment policies which are aimed at improving health
care at all levels.
Promethazine and other anti-histamines are routinely
used as adjunct to chloroquine in the treatment of malaria
in south-west Nigeria to reduce chloroquine-induced pru-
ritus and/or vomiting. The decline in chloroquine efficacy
in south-west Nigeria appears to coincide with the period
of increased prescription of sub-therapeutic doses of chlo-
roquine and decreased co-administration of anti-hista-
mines with chloroquine. Drug pressure and exposure of
parasites to sub-therapeutic concentrations of anti-malar-
ial drugs represent positive inducers of drug resistance.
Although chlorpheniramine or promethazine are rou-
tinely used as adjunct to chloroquine in treatment of
malaria, the role of this prescription practice in the slow
emergence of drug resistant parasites in Nigeria is
unknown. Anti-histamines, including chlorpheniramine,
promethazine and cyproheptadine, have been shown to
enhance chloroquine activity by reversal of chloroquine
resistance in vitro and in vivo [14-16]. The efficacy of the
combination of chloroquine and chlorpheniramine in the
treatment of uncomplicated acute chloroquine resistant P.
falciparum  infection was confirmed in limited clinical
studies in southwest Nigeria [4,5]. In the present study,
there was an association between decreased frequency of
use of promethazine and emergence of chloroquine resist-
ance. Thus, inadvertent combination of chloroquine with
anti-histamines over the years may have contributed to
delay in emergence of resistance to chloroquine in south-
west Nigeria. A recent study also described beneficial
pharmacokinetic interactions between chlorpheniramine
and chloroquine [17]. These observations essentially rep-
resent a valuable proof of the principle for clinical appli-
cation of the reversal of resistance phenomenon.
The Nigerian Government adopted the use of ACT in
2005 and the current guideline for treatment of uncom-
plicated falciparum malaria in Nigeria is artemether-
lumefanthrine or artesunate-amodiaquine [18]. The
results from the present studies confirm the influence of
prescription of inappropriate doses of anti-malarial drug
on dissemination of drug resistance falciparum malaria
and the need to improve malaria treatment practices in
Nigeria. In the resistance dissemination years, the records
show that artemether was prescribed as monotherapy
despite the fact that it was not one of the drugs recom-
mended for management of malaria. Furthermore, in
Nigeria, anti-malarial drugs are obtainable over the coun-
ter without prescription thus there is a potential for mon-
otherapy with the artemisinins and the use of ACT in sub-
therapeutic doses. As Nigeria implements the use of ACT,
it becomes imperative that sub-standard doses of ACT are
not used at any level of health care delivery. Since the pri-
vate sector is a leading provider of malaria case manage-
ment in many endemic countries [12] and responsible for
treating over 50% of malaria cases in Nigeria, it is critical
that the private sector in addition to government sup-
ported health care providers are targeted for training pro-
grammes in malaria case management.
Conclusion
The study revealed that chloroquine was the most com-
monly prescribed anti-malarial drug throughout the
phases studied. The prescription of substandard doses of
chloroquine was more prevalent in the private hospital
than the government hospital coinciding with the period
of dissemination of resistance.
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